Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
22,960
Total Claims
$3.3M
Drug Cost
736
Beneficiaries
$4,431
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+315%
Cost per patient vs peers
$4,431 vs $1,068 avg
+93%
Brand preference vs peers
17.4% vs 9.0% avg
Brand vs Generic
Brand: 3,977 claims · $2.6M
Generic: 18,921 claims · $634K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Empagliflozin | 370 | $285K |
| Icosapent Ethyl | 569 | $271K |
| Lipase/Protease/Amylase | 175 | $252K |
| Dapagliflozin Propanediol | 279 | $211K |
| Denosumab | 106 | $183K |
| Sitagliptin Phosphate | 206 | $152K |
| Vortioxetine Hydrobromide | 265 | $148K |
| Linaclotide | 222 | $142K |
| Linagliptin | 159 | $108K |
| Apixaban | 149 | $104K |
| Finerenone | 136 | $102K |
| Tenofovir Alafenamide | 55 | $82K |
| Semaglutide | 66 | $74K |
| Icosapent Ethyl | 183 | $63K |
| Rivaroxaban | 88 | $56K |
Prescribing Profile
Patient Profile
76
Avg Age
64%
Female
1.05
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data